ClinicalTrials.gg
RecruitingNCT07381803Updated Aug 7, 2026

The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction

A Phase 3 interventional study of Fexofenadine 60 Mg Oral Tablet and Placebo in Zhejiang University, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jan 2025, registered Jan 2026).
  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,804
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 195 studies in Myocardial Infarction with a site in China — 63 open to participants now, 72 under way, 7 of them phase 3. Myocardial Infarction · China.

Planned enrollment
23rd of 106
2,804 · median 364
Started
2025
with 18 others
Phase 3
19 of 195
3 open now
Primary completion
2026-12
later than 27 of 71 live
Registered
176th of 195
by date

Among the 195 studies in Myocardial Infarction with a site in China, this one is the 23rd largest by planned enrollment of the 106 interventional ones that give a count, is one of 19 that started in 2025, is one of 19 in phase 3, reaches primary completion later than 27 of the 71 other live ones, and was the 176th registered.

Myocardial Infarction

2,272 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

63 of the 195 studies in Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Myocardial Infarction with a site in China, or all of them as a file.
02

Study summary

The goal of this study is o evaluate the prognostic effect of fexofenadine hydrochloride in patients with myocardial infarction

03

Conditions studied

  • Zhejiang University

Keywords

  • myocardial infarction
  • cardiac fibrosis
  • cardiac MRI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old.
  • Able to verbally confirm understanding of the trial risks, benefits, and treatment options of fexofenadine hydrochloride therapy. He/she or his/her legal representative must provide written prior to participating in the clinical trial.
  • Acute ST-segment elevation myocardial infarction (STEMI) occurring within 7 days, with diagnostic criteria including:

    i) Typical clinical symptoms: such as severe crushing pain in the retrosternal or precordial area, usually lasting more than 10-20 minutes, which may radiate to the left upper arm, jaw, neck, back, or shoulders, etc.; ii) Elevated serum cardiac troponin (cTn): at least one measurement above the (99th percentile of the reference upper limit); iii) ST-segment elevation: new ST-segment elevation at the J point in 2 adjacent leads.

  • Echocardiography indicating segmental wall motion abnormalities.

Exclusion criteria

Exclusion Criteria:

  • Need for long-term use of fexofenadine hydrochloride or other H1 receptor inhibitors.
  • Previous coronary artery bypass grafting (CABG) surgery.
  • History of severe renal failure with estimated (eGFR) \< 30 ml/min.
  • History of severe liver dysfunction.
  • History of concurrent severe infection, hepatobiliary obstruction, or malignant tumor.
  • Expected of less than 2 years due to non-cardiac diseases.
  • Currently receiving therapy.
  • Pregnant, potentially pregnant, or lactating women.
  • to the study drug or examinations.
  • Failure to provide written .
  • Presence of mechanical complications (ventricular septal defect, papillary muscle dysfunction, acute mitral regurgitation), cardiogenic shock unresponsive to vasopressors, acute left heart failure or pulmonary edema, or malignant arrhythmias uncontrolled by antiarrhythmic drugs at enrollment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
2,804 participants (estimated)

Study arms

  • Placebo comparator
    placebo

    Drug: Placebo

  • Experimental
    Fexofenadine

    60mg, BID

    Drug: Fexofenadine 60 Mg Oral Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Major adverse cardiovascular and cerebrovascular events (MACCE)

    MACCE within 24 months after randomization, including all-cause death, recurrent myocardial infarction, stroke, hospitalization for heart failure, outpatient or emergency visits due to worsening heart failure, and repeat revascularization driven by angina pectoris.

    Time frame: 24 months

Secondary outcomes

  1. All-cause death

    All-cause death between 2 groups

    Time frame: 24 months, 60 months after myocardial infarction

  2. Recurrent myocardial infarction

    Recurrent myocardial infarction between 2 groups

    Time frame: 24 and 60 months after myocardial infarction

  3. Stroke

    Stroke incidence between 2 groups

    Time frame: 24 and 60 months after myocardial infarction

  4. Hospitalization for heart failure

    The incidence of Hospitalization for heart failure between 2 groups

    Time frame: 24 and 60 months after myocardial infarction

  5. Repeat revascularization driven by angina pectoris

    Repeat revascularization driven by angina pectoris between 2 groups

    Time frame: 24 and 60 months after myocardial infarction

  6. Left ventricular ejection fraction (LVEF%)

    Comparison of the difference in left ventricular ejection fraction (LVEF%) measured by echocardiography between the two groups at 24 months after randomization compared to baseline.

    Time frame: 24 months after myocardial infarction

  7. Left ventricular end-systolic diameter (LVIDs)

    Comparison of the difference in left ventricular end-systolic diameter (LVIDs) measured by echocardiography between the two groups at 24 months after randomization compared to baseline.

    Time frame: 24 months after myocardial infarction

  8. Left ventricular end-diastolic diameter (LVIDd)

    Comparison of the difference in left ventricular end-diastolic diameter (LVIDd) measured by echocardiography between the two groups at 24 months after randomization compared to baseline.

    Time frame: 24 months after myocardial infarction

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 33 non-industry phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 73. This study's planned 23 months is below that.

Counting every sponsor, half of 57 studies reached it within 43 months; a quarter within 30 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Feb 2, 2026
StartActual
Jan 27, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07381803
Responsible party
Sponsor
First posted
Feb 2, 2026
Start date
Jan 27, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Aug 7, 2026

Study contacts

Cheng Ni
Contact
cescni@zju.edu.cn
+8615088555539

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexofenadine

Start the discussion